Retatrutide TFA
Based on 3 publication(s) in Google Scholar
Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity.
For research use only. We do not sell to patients.
- Purity: 99.47%
- Formula: C221H342N46O68.xC2HF3O2
- Molecular Weight:4731.33 (free base)
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Retatrutide TFA
More
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
-
IHC
Biological Activity
EC50 (for human): 5.79 (GCGR), 0.0643 (GIPR), 0.775 nM (GLP-1R)[1].
EC50 (for mouse): 2.32 (GCGR), 0.191 (GIPR), 0.794 nM (GLP-1R) [1].
Ki (for human): 5.6 (GCGR), 0.057 (GIPR), 7.2 nM (GLP-1)[1].
Retatrutide (LY3437943) TFA has efficacy for human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively[1].
Retatrutide has efficacy for mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively[1].
Retatrutide has binding affinity for human GCGR, GIPR, and GLP-1R with Ki values of 5.6, 0.057 and 7.2 nM, respectively[1].
Retatrutide has binding affinity for mouse GCGR, GIPR, and GLP-1R with Ki values of 73, 2.8 and 1.3 nM, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Retatrutide (s.c.; 10 mL/kg; cycle every 3 days; for 21 days) causes great body weight loss and increases energy expenditure through glucagon receptor activatio[1].
Retatrutide has safety and tolerability[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Appearance Solid
-
Molecular Weight 4731.33 (free base)
-
Formula C221H342N46O68.xC2HF3O2
-
Color White to off-white
-
Synonyms
LY3437943 TFA
-
Sequence
Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
-
Sequence Shortening
Y-{Aib}-QGTFTSDYSI-{α-Me-Leu}-LDK-{Lys(AEEA-γGlu-C20 diacid)}AQ-{Aib}-AFIEYLLEGGPSSGAPPPS-NH2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Int J Obes
Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison. [Abstract]2026 Feb 21. PMID: 41723268 -
Endocrine
Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice. [Abstract]2025 Jan;87(1):159-169. PMID: 39212900
Retatrutide TFA purchased from MedChemExpress. Usage Cited in: Endocrine. 2025 Jan;87(1):159-169. [Abstract]
The mice received daily subcutaneous injections of 10 nmol/kg of Retatrutide for 10 weeks. Changes in fasting blood glucose (FBG) of mice in each group were recorded.
Retatrutide TFA purchased from MedChemExpress. Usage Cited in: Endocrine. 2025 Jan;87(1):159-169. [Abstract]
The mice received daily subcutaneous injections of 10 nmol/kg of Retatrutide for 10 weeks. Representative HE and PAS stained images of the kidneys of mice in each group were obtained.
Retatrutide TFA purchased from MedChemExpress. Usage Cited in: Endocrine. 2025 Jan;87(1):159-169. [Abstract]
The mice received daily subcutaneous injections of 10 nmol/kg of Retatrutide for 10 weeks. Representative immunohistochemical staining of TNF-α, Caspase-1, NLRP3, fibronectin, collagen I, and α-SMA in renal tissue of mice in each group was performed.
-
NPJ Metab Health Dis
Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression. [Abstract]2025;3(1):10. PMID: 40094000
Retatrutide TFA purchased from MedChemExpress. Usage Cited in: NPJ Metab Health Dis. 2025;3(1):10. [Abstract]
Mice were subcutaneously administered either Veh, 30 nmol/kg Retatrutide, or 30 nmol/kg SEMA every other day before the initiation of the dark cycle at 5 pm. Survival curves were plotted as % of mice tumor-free for each group.
Retatrutide TFA purchased from MedChemExpress. Usage Cited in: NPJ Metab Health Dis. 2025;3(1):10. [Abstract]
Mice were subcutaneously administered either Veh, 30 nmol/kg Retatrutide, or 30 nmol/kg SEMA every other day before the initiation of the dark cycle at 5 pm. Frequencies of CD45+ cells/live cells were shown.
Solvent & Solubility
DMSO : ≥ 100 mg/mL
0.5 M NH4OH : 50 mg/mL (Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (294 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Retatrutide TFA Related Classifications
HY-P3506A Related Classifications
Powered by Bioz